[Significance of preoperative TAE as an adjuvant therapy for hepatocellular carcinoma].
In 304 patients with hepatocellular carcinoma who underwent hepatic resection, 162 patients received chemoembolization before surgery (group A) and the remaining 142 patients received no therapy before surgery (group B). The 5-year disease-free survival (DFS) of group A and B were 36% and 21%, respectively, and there were no significant differences between them. In the groups of patients with good liver function (Child A), or patients with solitary tumor, or patients with tumors more than 5 cm in size, DFSs of group A were significantly better than those of group B. The difference of DFS between group A and B was largest in the group of the patients with tumors more than 5 cm in size.
Sasaki
Y
Y
Dept. of Surgery, Center for Adult Diseases, Osaka.
Imaoka
S
S
Masutani
S
S
Iwamoto
S
S
Kishimoto
S
S
Nakamori
S
S
Kameyama
M
M
Ohigashi
H
H
Hiratsuka
M
M
Ishikawa
O
O
D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D011300:Preoperative Care; D011379:Prognosis; D015996:Survival Rate
D015251:Epirubicin; D004317:Doxorubicin; D002945:Cisplatin